Literature DB >> 1755979

Control of human immunodeficiency virus replication by the tat, rev, nef and protease genes.

J Karn1.   

Abstract

Immediately after infection, human immunodeficiency virus directs the synthesis of three regulatory proteins tat, rev and nef that together allow the synthesis of the structural proteins of the virus after a delay of several hours. Viral mRNA production is controlled by the tat gene, which appears to stimulate elongation by RNA polymerase II, and the rev gene, which allows the accumulation of unspliced or partially spliced mRNAs in the cytoplasm. The nef gene is dispensible for virus growth but may limit virus spread by downregulating the levels of cellular surface proteins such as the CD4 receptor. Virus maturation also depends critically on the protease gene which allows the orderly rearrangement of the viral core structures in newly budded virions as well as the vpu and vif genes which allow efficient production of mature envelope glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1755979     DOI: 10.1016/0952-7915(91)90016-t

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  10 in total

1.  Stereospecificity of short Rev-derived peptide interactions with RRE IIB RNA.

Authors:  Alexander Litovchick; Robert R Rando
Journal:  RNA       Date:  2003-08       Impact factor: 4.942

2.  SMAD proteins of oligodendroglial cells regulate transcription of JC virus early and late genes coordinately with the Tat protein of human immunodeficiency virus type 1.

Authors:  Michelle R Stettner; Jonas A Nance; Clayton A Wright; Yayoi Kinoshita; Woong-Ki Kim; Susan Morgello; Jay Rappaport; Kamel Khalili; Jennifer Gordon; Edward M Johnson
Journal:  J Gen Virol       Date:  2009-05-06       Impact factor: 3.891

Review 3.  Regulation of eukaryotic gene expression by transcriptional attenuation.

Authors:  S Wright
Journal:  Mol Biol Cell       Date:  1993-07       Impact factor: 4.138

4.  Design and synthesis of RNA miniduplexes via a synthetic linker approach. 2. Generation of covalently closed, double-stranded cyclic HIV-1 TAR RNA analogs with high Tat-binding affinity.

Authors:  M Y X Ma; K McCallum; S C Climie; R Kuperman; W C Lin; M Sumner-Smith; R W Barnett
Journal:  Nucleic Acids Res       Date:  1993-06-11       Impact factor: 16.971

5.  Cellular protein modulates effects of human immunodeficiency virus type 1 Rev.

Authors:  Y Luo; H Yu; B M Peterlin
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

6.  Effects of Tat proteins and Tat mutants of different human immunodeficiency virus type 1 clades on glial JC virus early and late gene transcription.

Authors:  Clayton A Wright; Jonas A Nance; Edward M Johnson
Journal:  J Gen Virol       Date:  2012-11-14       Impact factor: 3.891

7.  Functional analysis of interactions between Tat and the trans-activation response element of human immunodeficiency virus type 1 in cells.

Authors:  Y Luo; S J Madore; T G Parslow; B R Cullen; B M Peterlin
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

8.  Methylphosphonate mapping of phosphate contacts critical for RNA recognition by the human immunodeficiency virus tat and rev proteins.

Authors:  C E Pritchard; J A Grasby; F Hamy; A M Zacharek; M Singh; J Karn; M J Gait
Journal:  Nucleic Acids Res       Date:  1994-07-11       Impact factor: 16.971

Review 9.  Human immunodeficiency virus type 1 infection of the brain.

Authors:  W J Atwood; J R Berger; R Kaderman; C S Tornatore; E O Major
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

10.  Exosomes containing HIV protein Nef reorganize lipid rafts potentiating inflammatory response in bystander cells.

Authors:  Nigora Mukhamedova; Anh Hoang; Dragana Dragoljevic; Larisa Dubrovsky; Tatiana Pushkarsky; Hann Low; Michael Ditiatkovski; Ying Fu; Ryunosuke Ohkawa; Peter J Meikle; Anelia Horvath; Beda Brichacek; Yury I Miller; Andrew Murphy; Michael Bukrinsky; Dmitri Sviridov
Journal:  PLoS Pathog       Date:  2019-07-25       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.